Kaplan Solomon A, Cohen Pinchas
Department of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095-1752, USA.
J Clin Endocrinol Metab. 2007 Dec;92(12):4529-35. doi: 10.1210/jc.2007-0526. Epub 2007 Nov 6.
The somatomedin/IGF hypothesis was based on the observation that GH was inactive when added to an in vitro incubation system but required a GH-dependent substance in the circulation to mediate its activity. Newer experimental evidence has led to several modifications of the hypothesis, but none of the proposed modifications accounts for all of the integrated actions of GH and IGF-I. In this paper, we propose an augmentative/counteractive modification of the existing hypothesis that takes into account all the actions of the GH-IGF system.
The modification is based on experimental evidence published since the hypothesis was originally developed.
The modification is based on an integration of the results of published experimental evidence regarding the actions of GH and the IGF complex.
We propose a new augmentative/counteractive modification of the hypothesis that the actions of the GH-IGF system provide a distinct evolutionary advantage to the organism by augmenting the anabolic actions of GH while countering its potentially deleterious effects of hyperglycemia and depletion of lipid stores.
生长调节素/胰岛素样生长因子(somatomedin/IGF)假说基于以下观察结果:当将生长激素(GH)添加到体外培养系统中时,它是无活性的,但需要循环中一种依赖GH的物质来介导其活性。更新的实验证据导致了对该假说的若干修正,但所提出的修正均未解释GH和IGF-I的所有整合作用。在本文中,我们提出了对现有假说的一种增强/对抗性修正,该修正考虑了GH-IGF系统的所有作用。
该修正是基于自该假说最初提出以来发表的实验证据。
该修正是基于对已发表的关于GH和IGF复合物作用的实验证据结果的整合。
我们提出了对该假说的一种新的增强/对抗性修正,即GH-IGF系统的作用通过增强GH的合成代谢作用同时对抗其高血糖和脂质储备耗竭的潜在有害影响,为生物体提供了独特的进化优势。